New advances & research
Our associations and membership with global Lyme organisations mean that we are collaborating and consulting at a global level with top Lyme specialists on a regular basis to share, learn and adopt the latest methods and treatments that can help our patients.
Organisations such as: ILADS (International Lyme & Associated Diseases Society), ILADEF (International Lyme & Associated Diseases Educational Foundation), GLXG (Global LymeXpert Group), Infectolab Americas, and top European laboratories connect us to reliable research, diagnostics, and science and evidence-based treatments that help our patients get better safely.
World leading tick-borne specialists such as Dr Carsten Nicolaus and others, give our clinic access to the top clinical care methods and decades of experience treating patients with the complexities that this disease presents.
Lyme disease is still a very underfunded and little recognised disease amongst most health care institutions and practitioners worldwide.
The researchers, scientists, doctors and practitioners who pursue careers working with Lyme disease, often risk their careers and reputation in the pursuit of a greater understanding and acceptance of this disease. As such, new diagnostics, medications and treatment can take time to develop.
But there is a strong sense of purpose and a guiding mission to help amongst many in the Lyme world and we count ourselves part of that global community who work and support to find the best diagnostic, treatment and care available for our patients.
As a clinic we pride ourselves on being open to adopting new methods, practices and treatments that are safe and that will benefit our patients, and we will continue to update this page with any new research or medical advances that we support.
One of the more recent medications that started trialling in the USA in 2019, and by our clinic in 2020, is Disulfiram (Antabuse) which has shown great results in a number of chronic Lyme cases.
Dr Jayakumar Rajadas, Head of the Stanford Biomaterials and Advanced Drug Delivery Laboratory at Stanford University, first discovered Disulfiram’s efficacy against Lyme disease in 2016 and there have been a number of conferences and symposiums amongst Lyme experts since then to share knowledge and experience of this drug on patients.
Our Lyme team, including Dr Nicolaus, have been part of these collaborative groups following the progress of Dr Rajadas and the work he is doing on Disulfiram trials and therapy for Lyme patients. There are a number of clinics trialling this drug and working to establish the optimal dose as well as the longevity of treatment for Lyme patients.
We have been using Disulfiram with a small number of patients, who are already on our long-term treatment programme and we have had some encouraging results to date. We use disulfiram with caution ensuring that we monitor a patient’s symptoms and bloodwork frequently (every 2wks) particularly early on in the treatment.
The FDA approved Disulfiram drug molecule is demonstrating good bioavailability, able to pass the blood–brain barrier which helps its effect in the central nervous system as well as reaching deep connective tissue where many borrelia persister cells reside. Though most of the studies are concerned with the use of the drug molecule in alcoholism, recent studies are showing it as a safe drug that can be repurposed for its antibacterial potential.
It should be noted that Disulfiram is a potent drug for Lyme patients and incorrect doses for Lyme patients can lead to serious side effects and herxheimer reactions. We note there are a number of Lyme practitioners and online support groups where dosages are shared amongst patients and we strongly recommend you do not try this until you have consulted with an official Lyme doctor who has been trained and supported by the ILADS groups of doctors currently using this drug.